All News
Decreasing immunogenicity, improving efficacy of pegloticase in gout
At #ACR20 three different medications are reviewed in different studies to decrease the immunogenicity of pegloticase – Methotrexate, Azathioprine and Mycophenolate Mofetil.
Read Article
Dr. Anthony Fauci’s session has been of the most popular lectures at #ACR20! Checkout highlights from his talk below!
@RheumNow https://t.co/720LUTIncJ
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Severe manifestations in #COVID19 infection. Dr Fauci #ACR20 @RheumNow Cytokine storm ⚡️⚡️⛈🌩 https://t.co/qsFjjP5iKG
Sole RetamozoSole ( View Tweet)
“We remain cautiously optimistic that we will have a safe, effective vaccine based on animal studies.” Here is an up-to-date list of COVID-19 trials as discussed at #ACR20 by Dr. A. Fauci @RheumNow https://t.co/DAoLGGtw1A
Dr. Rachel Tate uptoTate ( View Tweet)
RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by @Novartis. All content chosen by RheumNow + its Faculty.
Dr. John Cush RheumNow ( View Tweet)
Fauci: Common endpoints, common parameters provide "bridge" between #COVID19 vaccine trials. "We are cautiously optimistic" for a vaccine "by the end of the calendar year" because of favorable animal studies, though distribution will be later #ACR20 @Rheumnow. https://t.co/vPLEYiGKam
Eric Dein ejdein1 ( View Tweet)
A reminder or the fundamentals to curbing COVID19 per Dr. Anthony Fauci at #ACR20:
1. Everyone needs to wear a mask
2. Maintain 6 feet distance from others
3. Avoid crowds & congregations
4. Outdoor better than indoors
5. Wash your hands frequently
@RheumNow @LCalabreseDO https://t.co/khLS7V2A3b
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
“If we follow these five fundamentals we will not see the surging (of COVID-19)” Dr. Fauci #ACR20 @RheumNow https://t.co/dcPUmvUdcc
Dr. Rachel Tate uptoTate ( View Tweet)
It doesn't take a brilliant mind to hear the fundamentals, but its still nice to hear it from a brilliant mind #ACR20 @Rheumnow. https://t.co/Ad6GhHLk6C
Eric Dein ejdein1 ( View Tweet)
The one time at #ACR20 that only one sceen is on! #LTF @FauciFan @RheumNow so much respect for Dr Fauci! https://t.co/jhvlc8Py7R
Bella Mehta bella_mehta ( View Tweet)
Withdrawal of MMF may be safely in #SLE patients in remission #ACR20 @RheumNow Dr Chakravarty https://t.co/xnpagKNu96
Sole RetamozoSole ( View Tweet)
Rheumies, are you tuning to Dr. Fauci’s lecture live at #ACR20? @RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
A short break after an amazing lecture on IL6... summary points to come after a take a few sips do coffee and take in this beautiful day and view. #ACR20 @RheumNow @CCalabreseDO https://t.co/cDqKpECBPx
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
The use of telephone consultations as an additive tool in the outpatient care of patients with rheumatic disease showed good acceptance. Further work to study implementation of telephone and/or video consultations in clinics @RheumNow #ACR20 Abstr#0599
Dr. Antoni Chan synovialjoints ( View Tweet)
Pearls from @anisha_dua for differentiating atherosclerosis vs. vasculitis inflammation on imaging:
1. Look at the Axillary arteries - they tend to be less likely affected by atherosclerosis
2. Vasculitic lesions tend to be concentric & longer/continuous
#ACR20 #RheumTwitter
Adam Kilian MD KilianMD ( View Tweet)
Evidence-Based Guidance for Optimizing Gout #ACR20 Reminding us of cardioprotective effect of anti-inflammatory gout management with colchicine. https://t.co/TmsrRd2vFD
Jilaine Bolek Berquist BolekBerqui ( View Tweet)
@AngusWorthing @r_burmester Is the ‘thieves’ market’ session named after our history of stealing drugs? 😱 😂
Puja Mehta 🧩 DrPujaMehta1 ( View Tweet)
Today's #ACR20 lecture @r_burmester shows the biologic revolution was a result of serendipity -- this will spark the long-awaited new & improved name of our profession: serendipitology! Hi I'm Dr. Worthing I'm a Serendipitologist. I use drugs intended for infections, cancer etc.! https://t.co/buDqwAVK9u
Angus Worthing MD AngusWorthing ( View Tweet)
Dr Joan Merrill presents a phase 2 trial
use of Iberdomide in patients with #SLE
-Novel MOA —> blocks TF Ailos and Ikaros
Conclusion
-Primary end point was met at week 24
-Effects greater in Aiolos high/Type 2 IFN high
-Iverdomdie was tolerated well
#Lupus
#ACR20
#ACRambassador https://t.co/zpQR9ceV7p
Mohammad A. Ursani MD, RhMSUS DrMAUrsani ( View Tweet)
We need to start utilizing and normalizing anti phosphatidylserine/prothrombin antibody ordering in clinical practice #ACR20 https://t.co/LeeHnuX9x0
Emily Littlejohn ELittlejohnDO ( View Tweet)